Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from PYC Therapeutics Limited ( (AU:PYC) ).
PYC Therapeutics has disclosed a change in the holdings of director Dr Rohan Hockings, who acquired 82,550 fully paid shares via an on-market purchase, increasing his direct stake from 213,360 to 295,910 shares. The transaction, valued at $99,883, signals a higher personal financial commitment by the chief executive to the company’s equity.
In addition, Dr Hockings has been offered 1.5 million unlisted options under the company’s Long Term Incentive Plan, exercisable at $2.52 within 48 months, with vesting scheduled in two tranches after 12 and 24 months subject to shareholder approval. This structure is designed to incentivise long-term performance and further align management interests with those of shareholders, potentially impacting future dilution and executive retention dynamics.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a biotechnology company focused on developing therapeutic treatments, leveraging long-term incentive structures to align executive interests with shareholders. The company is listed on the ASX and manages its capital structure and executive equity through a combination of fully paid shares and option-based incentives.
Average Trading Volume: 1,288,036
Technical Sentiment Signal: Buy
Current Market Cap: A$1.2B
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.